Direct Medical Costs of Serious Gastrointestinal Ulcers among Users of NSAIDs
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The occurrence and prevention of gastrointestinal ulcers during use of NSAIDs has become a major healthcare issue.
To determine the direct medical costs of serious NSAID-related ulcer complications.
An observational cost-of-illness study was conducted in a large general hospital serving a population of 152 989 persons. From November 2001 to December 2003 all consecutive patients hospitalised with serious NSAID-related ulcer complications were identified. Serious NSAID-related ulcer complications were defined as ulcerations of the stomach or proximal duodenum causing perforation, obstruction or bleeding that occurred during the use of NSAIDs, necessitating hospitalisation of the patient. Data were retrieved with respect to days hospitalised and the number and type of diagnostic and therapeutic interventions. The main outcome measure was estimated mean direct medical costs of resources used.
A total of 104 patients were hospitalised with serious NSAID-related ulcer complications (incidence 31.4 per 100 000 persons per year). Most patients were elderly (mean 70.4 years, SD 16.7). In-hospital mortality was 10.6%. Mean direct medical costs were €8375 (95% CI 7067, 10 393). On the basis of these results, we estimated that approximately 5105 people are hospitalised with serious NSAID-related ulcer complications in The Netherlands each year, of whom 541 die in hospital. The total annual direct medical costs for serious NSAID-related ulcer complications in The Netherlands were estimated to be €42 754 375 (95% CI 36 077 035, 53 056 265).
Serious NSAID-related ulcer complications have a mortality rate of 10.6% in The Netherlands and the annual direct medical costs to the country of such complications are approximately €42 750 000.
- Verstappen, SMM, Verkleij, H, Bijlsma, JWJ (2004) Determinants of direct costs in Dutch rheumatoid arthritis patients. Ann Rheum Dis 63: pp. 817-24 CrossRef
- Bombardier, C, Laine, L, Reicin, A (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. N Engl J Med 343: pp. 1520-8 CrossRef
- Silverstein, FE, Faich, G, Goldstein, JL (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284: pp. 1247-55 CrossRef
- Rostom, A, Dube, C, Wells, G (2002) Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev.
- Leest, HTJI, Dieten, HEM, Tulder, MW (2004) Costs of treating bleeding and perforated peptic ulcers in The Netherlands. J Rheumatol 31: pp. 788-91
- Chevat, C, Pena, BM, Al, MJ (2001) Healthcare resource utilisation and costs of treating NSAID-associated gastrointestinal toxicity: a multinational perspective. Pharmacoeconomics 19: pp. 17-32 CrossRef
- Herings, RMC, Klungel, OH (2001) An epidemiological approach to assess the economic burden of NSAID-induced gastrointestinal events in The Netherlands. Pharmacoeconomics 19: pp. 655-65 CrossRef
- National Center for Health Statistics. Classifications of diseases and functioning & disability [online]. Available from URL: http://www.cdc.gov/nchs/icd9.htm [Accessed 2007 Jul 1]
- Oosterbrink, JB, Bouwmans, CAM, Koopmanschap, MA (2004) Guideline for cost-of-illness study: methods and guideline-rates for economic evaluations in health-care (in Dutch). College voor Zorgverzekeringen, Diemen
- Tariff book medical specialists. Utrecht: College Tarieven Gezondheidszorg, 1999
- Tariff list hospitals. Utrecht: College Tarieven Gezondheidszorg, 1999
- CBS; Statistics Netherlands. Population dynamics by birth, death and migration per region [online]. Available from URL: http://statline.cbs.nl [Accessed 2007 Jul 1]
- Efron, B, Tibshirani, R (1986) Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Stat Sci 1: pp. 54-77 CrossRef
- Briggs, AW, Wonderling, DE, Mooney, CZ (1997) Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 6: pp. 327-40 CrossRef
- Sheldon, T (2006) Dutch doctors call for action on drug safety. BMJ 333: pp. 1238 CrossRef
- Direct Medical Costs of Serious Gastrointestinal Ulcers among Users of NSAIDs
Drugs & Aging
Volume 24, Issue 8 , pp 681-690
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente Hospital, and University of Twente, Enschede, The Netherlands
- 2. Groningen University Institute for Drug Exploration (GUIDE), Department of Social Pharmacy, Pharmacoepidemiology and Pharmacotherapy, Groningen University, Groningen, The Netherlands